The women's health market is expected to prosper as a result of factors such as the rising prevalence of breast cancer, an increase in menstrual disorders and infertility issues in women, and
- The ESR1 mutated metastatic breast cancer market is witnessing the expected launch of three emerging therapies in the first-line market. Similarly, few therapies are also expected to launch